Clinical Data on Salarius Pharmaceuticals’ Seclidemstat in Patients with MDS and CMML Presented at the 2024 European Hematology Association Annual Meeting Jun 17, 2024 08:00AM
Salarius Pharmaceuticals (SLRX) Announces 1-for-8 Reverse Stock Split Jun 12, 2024 08:00AM
Salarius Pharmaceuticals Announces 1-for-8 Reverse Stock Split Jun 12, 2024 08:00AM
Salarius Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update Mar 22, 2024 04:05PM
Salarius Pharmaceuticals (SLRX) Issues Update on Strategic Review Process, Will Support Ongoing Seclidemstat Clinical Trials by Further Cost Cuts Feb 22, 2024 08:00AM
View Older Stories

Feb 22, 2024 08:00AM Salarius Provides Update on Strategic Review Process and Plans to Support Ongoing Seclidemstat Clinical Trials by Further Reducing Expenses
Jan 16, 2024 08:17AM Salarius Pharmaceuticals, Inc. (SLRX) Issued U.S. Patent for Next-Generation Targeted Protein Degraders
Jan 16, 2024 08:00AM Salarius Pharmaceuticals Issued U.S. Patent for Next-Generation Targeted Protein Degraders
Jan 3, 2024 08:54AM Salarius Pharmaceuticals (SLRX) Announces FDA Removal of Clinical Hold on Seclidemstat Trial
Jan 3, 2024 08:30AM Investigator-initiated Phase 1/2 Clinical Trial Using Salarius Pharmaceuticals’ Seclidemstat in Combination with Azacitidine to Treat Hematologic Cancers Resumes Patient Enrollment
Nov 7, 2023 08:31AM Salarius Pharmaceuticals, Inc. (SLRX) Completes FDA Type B Meeting for Seclidemstat Ewing Sarcoma Development Program
Nov 7, 2023 08:30AM Salarius Completes FDA Type B Meeting for Seclidemstat Ewing Sarcoma Development Program
Aug 10, 2023 04:05PM Salarius Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides a Business Update
Aug 8, 2023 04:10PM Salarius Pharmaceuticals (SLRX) Announces Plans to Explore Strategic Alternatives and Implement Measures to Extend its Resources
Aug 8, 2023 04:05PM Salarius Pharmaceuticals Announces Plans to Explore Strategic Alternatives and Implement Measures to Extend its Resources
May 11, 2023 08:00AM Salarius Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides a Business Update
May 9, 2023 08:00AM Salarius (SLRX) Announces FDA Removes Partial Clinical Hold on Phase 1/2 Trial of Seclidemstat
May 9, 2023 08:00AM FDA Removes Partial Clinical Hold on Salarius Pharmaceuticals’ Phase 1/2 Clinical Trial with Seclidemstat in Patients with Ewing Sarcoma
May 1, 2023 08:32AM Salarius Pharmaceuticals (SLRX) Reports No Adverse Safety Signals from Two Toxicology Studies of SP-3164
May 1, 2023 08:30AM Salarius Pharmaceuticals Reports No Adverse Safety Signals from Two Good Laboratory Practice Toxicology Studies with its Targeted Protein Degrader SP-3164
Apr 20, 2023 08:30AM Salarius Pharmaceuticals Presents Compelling Data in Two SP-3164 Targeted Protein Degrader Posters at the American Association for Cancer Research Annual Meeting
Apr 4, 2023 04:02PM Salarius Pharmaceuticals to Present at the Diamond Equity Research Emerging Growth Invitational Conference
Mar 27, 2023 08:30AM Salarius Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
Mar 15, 2023 11:00AM Salarius Pharmaceuticals Announces Two Abstracts Accepted for Presentation at the American Association for Cancer Research Annual Meeting
Mar 7, 2023 08:00AM Salarius Pharmaceuticals to Present In Vitro Data on Seclidemstat in Small Cell Lung Cancer at the Keystone Symposia
Feb 16, 2023 08:32AM Salarius Pharmaceuticals, Inc. (SLRX) Receives $1.48M from the Cancer Prevention and Research Institute of Texas
Feb 16, 2023 08:30AM Salarius Pharmaceuticals Receives $1.48 Million from the Cancer Prevention and Research Institute of Texas
Jan 27, 2023 08:30AM Salarius Pharmaceuticals Presents SP-3164 Preclinical Data at the Inaugural Molecular Glue Drug Development Summit
Jan 19, 2023 08:30AM Salarius Pharmaceuticals to Present SP-3164 Targeted Protein Degrader Preclinical Data at the Inaugural Molecular Glue Drug Development Summit
Jan 5, 2023 08:00AM Salarius Pharmaceuticals Announces Issuance of New U.S. Patent for Next-Generation Targeted Protein Degraders
Dec 13, 2022 08:12AM Salarius Pharmaceuticals (SLRX) Announces Investigators Present Clinical Data on Seclidemstat in Patients with MDS and CMML
Dec 13, 2022 08:01AM Investigators Present Clinical Data on Salarius Pharmaceuticals’ Seclidemstat in Patients with MDS and CMML at the 2022 American Society of Hematology Annual Meeting
Dec 13, 2022 08:00AM Salarius Pharmaceuticals Presents SP-3164 Data Demonstrating Activity in Preclinical Lymphoma Models at the American Society of Hematology Annual Meeting
Dec 8, 2022 08:00AM Salarius Pharmaceuticals to Hold Conference Call to Discuss Recent Clinical and Preclinical Data on Lead Programs, Including Presentations at ASH
Dec 1, 2022 08:06AM Salarius Pharmaceuticals, Inc. (SLRX) Announces Interim Results from Phase 1/2 Trial of Seclidemstat as a Treatment for Ewing Sarcoma and FET-Rearranged Sarcomas
Dec 1, 2022 08:00AM Salarius Pharmaceuticals Announces Interim Results from Phase 1/2 Trial of Seclidemstat as a Treatment for Ewing Sarcoma and FET-Rearranged Sarcomas
Nov 10, 2022 08:30AM Salarius Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Update
Nov 3, 2022 09:57AM Salarius Pharmaceuticals Announces Two Presentations at the 2022 American Society of Hematology Annual Meeting
Oct 27, 2022 08:30AM Salarius Pharmaceuticals Presents Favorable Preclinical Data on SP-3164 at the 5th Annual Targeted Protein Degradation Conference
Oct 19, 2022 08:30AM Salarius Pharmaceuticals to Present SP-3164 at the 5th Annual Targeted Protein Degradation Conference
Oct 18, 2022 08:37AM Salarius Pharmaceuticals (SLRX) Announces Pause in New Patient Enrollment in its Phase 1/2 Trial of Seclidemstat in Ewing Sarcoma and FET-Rearranged Sarcomas
Oct 18, 2022 08:30AM Salarius Pharmaceuticals Announces Pause in New Patient Enrollment in its Phase 1/2 Trial of Seclidemstat in Ewing Sarcoma and FET-Rearranged Sarcomas
Oct 14, 2022 08:44AM Salarius Pharmaceuticals (SLRX) Announces 1-for-25 Reverse Stock Split
Oct 14, 2022 08:43AM Salarius Pharmaceuticals Announces 1-for-25 Reverse Stock Split
Sep 20, 2022 12:00PM Salarius Pharmaceuticals to Present at the 2022 Ladenburg Thalmann Healthcare Conference
Sep 13, 2022 08:05AM Salarius Pharmaceuticals, Inc. (SLRX) CEO Issues Letter to Shareholders
Sep 13, 2022 08:00AM Salarius Pharmaceuticals CEO Issues Letter to Stockholders
Aug 22, 2022 08:30AM Salarius Pharmaceuticals Adds Two Mayo Clinic Sites to its Ongoing Phase 1/2 Trial of Seclidemstat as a Treatment for Ewing’s Sarcoma and FET-Rearranged Sarcomas
Aug 8, 2022 08:30AM Salarius Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Update
Aug 4, 2022 08:30AM Salarius Pharmaceuticals Adds Seattle Cancer Care Alliance and Oregon Health & Sciences as Clinical Sites for its Ongoing Trial of Seclidemstat as a Treatment for Ewing Sarcoma and FET-Rearranged
Aug 2, 2022 08:30AM Salarius Pharmaceuticals and VolitionRx Enter into R&D Collaboration Agreement
Jul 29, 2022 09:15AM Salarius Pharmaceuticals to Host Second Quarter 2022 Financial Results and Business Update Conference Call on Monday, August 8, 2022
Jun 9, 2022 07:33AM Salarius Pharmaceuticals to Participate in BIO International Convention 2022
May 18, 2022 04:10PM Salarius Pharmaceuticals to Present at H.C. Wainwright Global Investment Conference
May 12, 2022 04:05PM Salarius Pharmaceuticals Reports Business Highlights with First Quarter 2022 Financial Results
View Older Stories